HM Venture Partners
Venture capitalSan Francisco · Seed–Late Stage · 7 people tracked
Find your way into HM Venture Partners
288 people in our graph share verified history with the HM Venture Partners team — schools, employers, funds. One of them is your warm intro.
Investment thesis
HM Venture Partners focuses on healthcare, investing in biotech and medtech companies globally and across all stages. It aims to help early- and growth-stage healthcare companies accelerate development by leveraging its team's deep domain expertise and an extensive ecosystem of academic institutions, physician networks, and industry experts. This network provides proprietary deal flow, clinical trial site access, and cross-border business development, particularly bridging the US and Chinese markets. The firm emphasizes identifying breakthrough innovations that address significant unmet medical needs and applies cycle-tested, flexible financing strategies to structure favorable transactions and create value. Its most recent fund, HM Healthcare Fund I, primarily targets healthcare breakthroughs in the US.
Source: firm website, verified Aug 7, 2026.
Team · 7 people
from the firm's website & public directories
What they invest in
from 25 of 31 portfolio companiesHealthtech ×18Biotech ×17Medical Devices ×13Digital Health ×4AI & Machine Learning ×2Deep Tech ×2FemTech ×2EdTech ×1
HQs:United States×15China×3Germany×1Denmark×1
Who they back
founder profiles across 13 portfolio companiesFounding team size:solo founder×82 founders×44+ founders×1
Investments · 31 tracked
founders shown can be your intro pathBy year:2025 · 12023 · 12020 · 12017 · 14 dated
Sagimet is a clinical-stage biopharmaceutical company developing therapies targeting fatty acid synthase (FASN) for metabolic diseases and oncology.
BiotechDigital HealthHealthtechMenlo Park, US
Rekha Hemrajani(Executive Officer)inMerdad Parsey(Executive Officer, Director)inDavid Happel(Chief Executive Officer & Director)Andreas Grauer(Chief Medical Officer)inThierry Chauche(Chief Financial Officer)inMarie O'Farrell(Chief Scientific Officer)in
Co-investorsAltium CapitalKleiner PerkinsNew Enterprise Associates (NEA)Westlake Village BioPartners
Arthrosi Therapeutics is a clinical-stage biopharmaceutical company developing treatments for gout, an inflammatory arthritis condition.
BiotechDigital HealthMedical DevicesSan Diego, US
Litain Yeh(Co-Founder & Chief Executive Officer)inShunqi Yan(Co-Founder & Chief Operating Officer)
Coherent Biopharma (Tongyi Pharmaceutical) is a biopharmaceutical company developing its proprietary Bi-targeting XDC (bi-XDC) conjugate drug platform to make previously undruggable targets treatable, with a focus on oncology.
BiotechDeep TechHealthtech
Baohua Huang(Founder & CEO)
GenFleet is a biopharmaceutical company developing novel drug therapies focused on RAS targeting and antibody-drug conjugates (ADCs) to address unmet clinical needs in cancer and other serious diseases.
AI & Machine LearningBiotechHealthtechMedical DevicesBeijing, CN
Qiang LU(Founder)in
Board吕强兰炯
Co-investorsPan-Lin Capital
GIE Medical is a clinical-stage medical device company developing the ProTractX3, a drug-coated balloon for treating benign strictures of the esophagus and bowel.
BiotechHealthtechMedical DevicesPlymouth, US
Lixiao Wang(Founder & Chief Executive Officer)inIan Schorn(Chief Operational Officer)inJames Ness(Chief Financial Officer)Harrison Malinoff(VP of Operations and Quality)Dave Hendrickson(VP of Research & Development)Drew McClure(VP of Market Development)in
HuidaGene develops CRISPR and RNA-guided gene editing technologies for therapeutic applications in neurology, ophthalmology, otology, myology, and hepatology.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesShanghai, CN
Hui Yang(Co-Founder and Chief Scientific Advisor)
KBP is a biotechnology research and development organization that discovers and develops new therapies for unmet medical needs.
Biotech
Co-investorsBay City Capital
Melodi Health is a medical device company focused on breast reconstruction and breast procedures, developing implantable combination devices with expertise in infection control and plastic reconstructive surgery.
FemTechHardwareHealthtechMedical DevicesMinneapolis, US
Sarah Worrell(Co-founder & Chief Executive Officer)inMichele Hilmer(Chief Strategy Officer)Hunter Moyer, MD(Chief Medical Officer)Kaitlyn Roth(VP Operations)inMatthew Hemsley(Director)Arikha Moses(Director)
Co-investorsEngage Venture Partners
Minnesota Medical Technologies develops and manufactures continence care products, specifically fecal incontinence management devices for individual patients.
Digital HealthHealthtechMedical DevicesStewartville, US
Philip J Conway(Executive Vice President – Operations (Founder))Sarah L Grinde(VP Marketing and Research & Development (Founder))Anthony J Conway(Chairman of the Board (Founder))Lonnie M Boe(Executive Secretary/Office Manager (Founder))
Neurotronic is developing Neuviant Multi-organ Denervation (MDN), an investigational catheter-based therapy that delivers ethanol to overactive sympathetic nerves near the kidneys and liver to lower blood sugar and blood pressure.
Newswise is a news distribution platform and press release service that connects journalists, public relations professionals, and the public with research news and expert sources across medical, science, life, and business sectors.
Marketing TechMedia & EntertainmentSaaS
Roger Johnson(Founder)inJessica Johnsonin
Novo Nordisk is a pharmaceutical company that develops and markets treatments for conditions including diabetes, obesity/weight management, and haemophilia, with products such as GLP-1 therapies.
BiotechHealthtechCopenhagen, DK
Maziar Mike Doustdarin
Co-investorsNovo Holdings
OncoC4 is a clinical-stage biopharmaceutical company developing immunotherapy treatments for cancer patients, based on research by its immunologist founders.
BiotechHealthtechRockville, US
Yang Liu(Co-founder)inPan Zheng(Co-founder)inMartin Devenport(Executive Officer)Michael Flaschen(Director)
Co-investors3E Bioventures Capital
First-in-class biologic drug targeting the CD24-Siglec innate immunity signaling pathway.
BiotechRockville, US
Pan Zheng(Executive Officer)Yang Liu(Executive Officer, Director)Martin Devenport(Executive Officer)
BoardMiao Hong(Director)Karen Liu(Director)inKun-Liang Guan(Director)
Co-investors3E Bioventures Capital
BiotechDallas, US
David Thompson(Executive Officer, Director)inBrian de Beaubien(Executive Officer, Director)Renee Ryan(Director)Jude Paganelli(Executive Officer, Director)
BoardMartin Sands(Director)Judson Cooper(Director)
Osteal Therapeutics is a clinical-stage pharmaceutical company developing novel treatments for orthopedic infections, particularly periprosthetic joint infections.
BiotechDigital HealthHealthtechMedical Devices
Brian de Beaubien, MD(Co-Founder & Chief Medical Officer)David Thompson(Chairman & CEO)in
Merck is a pharmaceutical company focused on developing medicines and vaccines for patients globally, guided by a science-led innovation strategy.
BiotechHealthtechMedical DevicesRahway, US
Co-investorsAisling CapitalAtlas VentureSanderling VenturesSPRINGROCK VENTURESThe Column Group
UC Davis is a public tier-one research university located in Davis, California, with additional campuses and centers including UC Davis Health in Sacramento and marine and environmental research labs.
EdTechDavis, US
Co-investorsDigitalDx VenturesThe March Group
Urotronic develops drug-coated balloons for interventional urology, including the Optilume products for treating benign prostatic hyperplasia (BPH) and urethral strictures.
HealthtechMedical DevicesPlymouth, US
Junfeng Wang(Director)David Perry(Executive Officer, Director)Tan Ching(Director)Hui Hu(Director, Promoter)Lixiao Wang(Director, Promoter)Doug Kohrs(Director)
Co-investorsEnterprise IrelandGilde HealthcareIreland Strategic Investment FundLegend CapitalLightstone VenturesMVM Life Science Partners+1 more
Verve Medical is developing the Verve RPD System, an investigational device for renal pelvic denervation—a minimally invasive catheter-based procedure that uses radiofrequency energy to disrupt overactive kidney nerves to lower blood pressure.
HealthtechMedical DevicesSanta Barbara, US
Terry Buelna(Chief Executive Officer/President/CFO)in
BoardWayne Wu(Director)
BioNTech develops immunotherapies that use the body's immune system to treat cancer, infectious diseases, and other serious illnesses.
BiotechHealthtech
Co-investorsPfizer Venture InvestmentsSalvia
Zepto develops a targeted liquid biopsy platform for infectious disease diagnostics, offering plasma-based molecular testing through its CLIA reference laboratory and an integrated sample-to-result platform for use in hospital laboratories.
BiotechHealthtechMedical Devices
Yongyong Zhang(Founder)in
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Arthrosi TherapeuticsGIEKBPMedbotsurgicalMinnesota Medical TechnologiesRestoramedicalSobi completes acquisition of Arthrosi Therapeutics
Exits · 3
1 IPOs · 2 acquisitions · showing 2Sagimet BiosciencesNASDAQ: SGMTKBPacq. by Novo Nordisk
Portfolio news
latest coverage across their companiesMinnesota Medical Technologies · nextinthenorth.com · Apr 21, 2026
Osteal Therapeutics · nasdaqprivatemarket.com · Oct 21, 2025
Arthrosi Therapeutics · finance.yahoo.com · Oct 9, 2025
OncoC4 · finsmes.com · Oct 2, 2025
Urotronic · fiercebiotech.com · Aug 26, 2025
Frequently asked questions
- How many investments has HM Venture Partners made?
- HM Venture Partners has 31 tracked investments, 3 of which have exited, including 1 dated in the last 24 months.
- What stage does HM Venture Partners invest at?
- HM Venture Partners invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does HM Venture Partners focus on?
- HM Venture Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is HM Venture Partners located?
- HM Venture Partners is headquartered in San Francisco, US.
- Does HM Venture Partners lead rounds?
- Yes, HM Venture Partners leads investment rounds.
- Who does HM Venture Partners co-invest with?
- HM Venture Partners most often shares deals with 3E Bioventures Capital, Atlas Venture, DigitalDx Ventures, among 16 tracked co-investors.
Similar investors
US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.
New Alliance Capital is a Shanghai-based private equity and venture capital firm founded in 2008, focused on technology-driven sectors. Its backers include state-owned enterprise groups, insurance capital, fund-of-funds, government guidance funds, and listed companies.
Bay City Capital is a venture capital firm founded in 1997 that has raised five venture funds totaling $1.3 billion in capital commitments and invested in more than 100 companies worldwide.
Gilde Healthcare is a specialist investment firm managing healthcare and climate-focused funds across venture & growth, and private equity strategies with a transatlantic team of sector specialists.
Clal Biotechnology Industries (TASE: CBI) is an Israeli life sciences investment firm listed on the Tel Aviv Stock Exchange, focused on identifying and developing ventures that create proprietary solutions for unmet medical needs.